EP1885459A1 - Compresse autocollante pour la peau et ensemble combine pour le soin cosmetique de la peau - Google Patents

Compresse autocollante pour la peau et ensemble combine pour le soin cosmetique de la peau

Info

Publication number
EP1885459A1
EP1885459A1 EP06725393A EP06725393A EP1885459A1 EP 1885459 A1 EP1885459 A1 EP 1885459A1 EP 06725393 A EP06725393 A EP 06725393A EP 06725393 A EP06725393 A EP 06725393A EP 1885459 A1 EP1885459 A1 EP 1885459A1
Authority
EP
European Patent Office
Prior art keywords
skin
matrix
active ingredient
support according
carnitine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06725393A
Other languages
German (de)
English (en)
Inventor
Sören JASPERS
Carsten Hartkopf
Christian GÄDE
Stefan Bodenschatz
Katharina Post
Jens Schulz
Karl-Heinz WÖLLER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beiersdorf AG
Original Assignee
Beiersdorf AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beiersdorf AG filed Critical Beiersdorf AG
Publication of EP1885459A1 publication Critical patent/EP1885459A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
    • A61K8/8147—Homopolymers or copolymers of acids; Metal or ammonium salts thereof, e.g. crotonic acid, (meth)acrylic acid; Compositions of derivatives of such polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/02—Adhesive bandages or dressings
    • A61F13/0203—Adhesive bandages or dressings with fluid retention members
    • A61F13/0206—Adhesive bandages or dressings with fluid retention members with absorbent fibrous layers, e.g. woven or non-woven absorbent pads or island dressings
    • A61F13/0209—Adhesive bandages or dressings with fluid retention members with absorbent fibrous layers, e.g. woven or non-woven absorbent pads or island dressings comprising superabsorbent material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/02—Adhesive bandages or dressings
    • A61F13/0203—Adhesive bandages or dressings with fluid retention members
    • A61F13/0213—Adhesive bandages or dressings with fluid retention members the fluid retention member being a layer of hydrocolloid, gel forming material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/02—Adhesive bandages or dressings
    • A61F13/0203—Adhesive bandages or dressings with fluid retention members
    • A61F13/0223—Adhesive bandages or dressings with fluid retention members characterized by parametric properties of the fluid retention layer, e.g. absorbency, wicking capacity, liquid distribution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/06—Bandages or dressings; Absorbent pads specially adapted for feet or legs; Corn-pads; Corn-rings
    • A61F13/08—Elastic stockings; for contracting aneurisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0208—Tissues; Wipes; Patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/90—Block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00361—Plasters
    • A61F2013/00902—Plasters containing means

Definitions

  • the present invention relates to a skin support comprising a matrix adherent to the skin comprising at least one cosmetic active ingredient and a combination with a skin wrap for producing an effective compression for the treatment of cellulite and / or stretch marks of the skin, such as stretch marks.
  • Cellulite (medical term: dermopanniculosis) is not a disease but a cosmetic problem.
  • the causes of cellulite are mainly due to the specific structure of the female skin and the response to the female hormones.
  • Fat cells are stored in the subcutaneous tissue. Their amount is already determined in the infant stage and can not be influenced by diet or exercise. In the fat cells, the fatty acids from the diet are converted into fats and embedded into the connective tissue like nodules. If these fats are not broken down for a long time (for example, sports), and the body is additionally over-fed, the cells can expand many times their size. The enlarged cells then push through the connective tissue and it comes to the dreaded orange peel, also known as cellulite.
  • the other consequences in old age are spider veins, varicose veins, thrombosis and leg ailments. Often the thighs are also storage for excess fat that is absorbed through the diet. The ugly, lateral thickening of the thighs, also called rider's trousers, combined with cellulitis often represent a great burden for those affected.
  • the lymph circulation is stimulated and toxins, fats and slag substances are eliminated from the body through the development of heat.
  • stretch marks are reduced, cellulite reduced and the so-called riding pants reduce after a few treatments.
  • anti-cellulite patches for example, "Perfect SNm Cellulite Patch” by L'Oreal
  • ingredients such as sea algae or caffeine promote the smoothing of unsightly dents.
  • the beauty patches make it easier for women who are tired to permanently cream, the application. This allows targeted treatment of severely affected areas.
  • the advantage of such a patch lies in the more than eight hours of continuous drug delivery of the patch. In addition, they can also be used at night
  • the CREALITE product from Creaderm uses nanotechnology for cellulite for the first time. With liposomes, caffeine gets into the skin through the skin.
  • CREALITE contains high-dose caffeine (2%) in a specially adapted carrier.
  • Caffeine deprives the cells of water and also inhibits the enzyme, cyclic M3 ', 5'-
  • WO 05/007127, WO 04/093865, WO 04/074216 and WO 04/060268 also show numerous cosmetic active ingredients and treatment methods for the treatment of cellulite.
  • EP 1181926 EP 728472 and EP 493151, in particular caffeine-containing cosmetics are disclosed for cellulite treatment.
  • Object of the present invention is to show alternatives for the treatment of cellulite.
  • Skin stretch marks are cracks in the subcutaneous tissue. They develop on the stomach, hips or chest. Striae are first bluish-red, later yellowish-white. They have a similar appearance to scars. They arise when the skin is overstretched and at the same time the skin's elasticity has decreased. A high cortisol level promotes the formation of stretch marks. This hormone causes the skin to hold more water and it reduces the elasticity of the skin.
  • Pregnant women, adolescents, competitive athletes, those on hormonal treatment, and those with high body weights are the main striatal groups.
  • stretch marks are present, they can no longer be completely reduced according to current knowledge. A reduction and alleviation is possible up to 50%. Also for laser treatments is that they usually do not bring the desired success. It is therefore also an object of the present invention to provide a skin pad which makes it possible to treat the stria-affected skin areas and to effect a cosmetic improvement of these skin areas.
  • the skin is exposed to ever-changing environmental conditions and is subject to a number of changes over time.
  • changes in barrier properties, skin-elasticity and elasticity, pigmentation and, in particular, as a result of exogenous influences also lead to different inflammatory reactions and, for example, to subsequent reactions of the skin to the action of UV radiation.
  • the barrier effect of the skin can be quantified by determining transepidermal water loss (TEWL). It is the evaporation of water from the inside of the body without the inclusion of water loss during sweating.
  • the determination of the TEWL value has proven to be extraordinarily informative and can be used for the diagnosis of chapped or chapped skin, for the determination of the compatibility of chemically different surfactants and the like.
  • the water content in the uppermost layer of skin is of utmost importance. It can be favorably influenced to a limited extent by introducing moisture regulators.
  • Cosmetic skin care is to be understood in the first place that the natural function of the skin as a barrier against environmental influences, e.g. Dirt, chemicals, micro-organisms, and against the loss of endogenous substances, e.g. Water, natural fats, electrolytes, fortified or restored.
  • environmental influences e.g. Dirt, chemicals, micro-organisms
  • endogenous substances e.g. Water, natural fats, electrolytes, fortified or restored.
  • the aim of skin care is also to compensate for the daily loss of fat and water loss of the skin. This is especially important when the natural regeneration capacity is insufficient.
  • skin care products are intended Protect the environment, especially against sun and wind, and delay the aging of the skin.
  • Exogenous factors such as UV light and chemical noxae can be cumulatively effective.
  • exogenous factors occur, e.g. The following structural damage and functional disorders in the skin:
  • cooling preparations which - applied to the skin or mucous membranes - moistening and cooling effect.
  • ionic compounds in particular ammonium salts
  • cooling agents are described as cooling agents.
  • Menthol, camphor and their derivatives, but also other essential oils lower the threshold of stimulation of the neuronal cold receptors and cause a feeling of cold. Frequently, however, they simultaneously increase blood circulation, which on the contrary causes a feeling of warmth.
  • the use of these substances, especially on irritated skin, is in any case problematic.
  • many of these compounds are poorly water-soluble. Their use is therefore limited to a few cosmetics and dermatics.
  • TTS Transdermal Therapeutic Systems
  • plaster, cosmetic / dermatological matrices and cosmetic / dermatological pads are used interchangeably below.
  • Transdermal therapeutic systems for delivery of active ingredients into and through the skin have been known for a long time and represent paving, in particular drug-doped systems.
  • this dosage form realizes a release kinetics of the first-order drug, whereby a constant level of active ingredient in the skin can be maintained over a very long period of time.
  • the time-dependent release of the cosmetic active substance from a TTS takes place as a function of its distribution coefficient TTS / skin and its diffusion in the area of the TTS
  • first-order release kinetics are achieved, allowing for equal amounts of release per unit of time.
  • transdermal systems well described in the literature represents matrix systems or monolithic systems in which the cosmetic active ingredient is incorporated directly into the pressure-sensitive adhesive.
  • Such an adhesive-containing, active substance-containing matrix is usually provided in the ready-to-use product on one side with a carrier which is impermeable to the active substance, on the opposite side there is a carrier film provided with a separating layer which is removed on the skin before application (sticking & sealing, no .42, 1998, pp. 26 to 30).
  • the above-mentioned properties of a TTS avoid frequently repeated application and loading of the skin with high concentrations of active ingredients and thus reduce the irritation of the skin, which is unavoidable with repeated application of liquid and semi-solid administration forms.
  • TTS are significantly improved user compliance, due to the ease and speed of application and long-term efficacy of transdermal therapeutic systems.
  • a basic requirement for a TTS is, on the one hand, a good adherence to the skin, which must be maintained over the entire period of the intended drug dosing, and, on the other hand, a residue-free removability of the TTS. Also, a painful redetachment of the active ingredient-containing patch after prolonged gestation is often observed.
  • adhesives which are coated in solution on the support u.a. also solvent-free systems, such as hot melt adhesives used. These are characterized by the fact that in the coating can be dispensed with the use of organic solvents and dispersants. Hot melt adhesives are converted by heating in a liquid form and applied as a melt on the respective plaster backing.
  • Transdermal therapeutic systems are usually applied to healthy, intact skin.
  • Cataplasms are then usually blended with glycerine, water or other suitable liquid substances with finely powdered Active ingredients prepared with the addition of essential oils.
  • Glycerol acts as a humectant to prevent premature dehydration when using the cataplasms. While natural thickening agents such as alumina etc. are used in the traditional Asian preparations, more and more modern synthetic raw materials, such as eg polyacrylic acid as gelling agent, are used for the production in recent decades. As a result, the generally pasty cataplasms can also be represented as hydrogel matrices with improved appearance and user-friendliness.
  • EP 1 136 057 describes an aqueous gel system for cosmetic use without a carrier or cover with a light transmission of min. 70%.
  • EP 0 507 160 describes cataplasms containing lidocaine.
  • a disadvantage of the cataplasms described is that many different individual components such as gelling agents, thickeners, plasticizers, humectants, stabilizers, emulsifiers, pH regulators, antioxidants, etc. are required for the preparation of the base matrices, and in case of active substance-containing cataplasms possibly additionally solubilizers and penetration accelerators. Since the adhesive behavior and consistency of such a matrix result from the interaction of all individual components, targeted product development / optimization with respect to these basic product requirements is correspondingly time-consuming and difficult.
  • polymer matrices especially gel matrices, polyacrylates
  • gel matrices are used, inter alia, as adhesive base and drug reservoir in transdermal systems. Such systems have sufficient adhesive power, especially on moist skin (buccal patches), but can not be completely removed if necessary due to insufficient cohesiveness.
  • Polyacrylic acid must be crosslinked to form a gel with a defined structure. The nature of the crosslinker contributes significantly to the structure of the resulting gel.
  • the usual crosslinking agents may be metal ions (eg: Al 3+ ions), or organic compounds.
  • Crosslinking with aluminum salts proceeds via the coordination of the oxygen functions of the polyacrylic acid to the Al 3+ ions. It forms a very dense gel with high viscosity, wherein the viscosity of the gel can be controlled only by the amount of crosslinker (Handbook of pressure sensitive adhesive technology, page 458 ff, 1999).
  • JP 11-228340 discloses polyacrylic acid-based gels which use Al + 3 compounds as crosslinkers. The use of the absolutely necessary aluminum compound as a crosslinking agent is limited, since otherwise the physical properties of the gel are impaired. If the proportion of aluminum crosslinker is too high, the gel becomes too hard.
  • crosslinking with multivalent metal ions e.g. US 3900610 (zinc salts), US 3770780 or US 3790533 (titanium compounds).
  • the ionic crosslinking with metal ions leads to hard, viscous and slightly sticky polymer gels (Handbook of Pressure Sensitive Adhesive Technology, page 458 ff, 1999).
  • EP 303445 discloses a monolayer gel matrix plaster based on water-soluble polymers.
  • Mandatory ingredients include clebopride or a pharmaceutically acceptable salt thereof as the active ingredient, water, water-absorbing agents, and water-soluble polymers.
  • water-soluble polymers one skilled in the art can select from a number of known polymers such as polyvinyl alcohol, gelatin, polyacrylic acid, sodium polyacrylates, methylcellulose, carboxymethylcellulose, polyvinylpyrrolidone, gum and other crosslinkable polymers, and mixtures thereof
  • EP 976382 describes a plaster containing a matrix consisting of a hydrophilic gelling in an aqueous phase system, formed from gelan gum and at least one other hydrocolloid. Claimed is Gelangummi mandatory. Gelan gum, as defined by specialist lexicons, is understood to mean hydrocolloids obtained from the following marine plants: Agardhiella tenera, Furcellaria fastigiata, Hypnea cervicornis, musciformis, spicifera, Suhria vitata. Likewise, the essential aspects of the self-adhesive properties, the adjustability of bond strength and elasticity of the resulting matrices are not mentioned.
  • a further problem in the crosslinking of polyacrylic acid to a self-adhesive matrix or gel is that a matrix once produced with defined physical properties, viscosity, tack etc. must have the same defined properties in a later production process. This reproducibility is with consuming or not to realize the currently known networking technologies.
  • the adhesive of the patch can be used as the drug-containing matrix.
  • hot-melt self-adhesive compositions have also been proposed for this purpose, for example in EP 0 663 431 A, EP 0 452 034 A, EP 0 305 757 A, DE-OS 43 10 012, DE-OS 42 22 334 and DE-OS. C 42 24 325.
  • active ingredients are here, when they are named, systemically acting listed.
  • Exemplary of active ingredient-containing patches are the circulation-promoting active ingredient patches called, which belong to the group of locally effective therapeutic systems.
  • the use of such patches is indicated for the treatment of rheumatic complaints, sciatica, lumbago, neck stiffness, shoulder-arm pain and muscle tension and strains, muscle soreness or muscle, joint and nerve pain in the musculoskeletal system.
  • Capsaicin and nonivamide are known active ingredients of such local, blood circulation-promoting patch. Due to their application to the musculoskeletal system they usually have to stick strongly. Usually, the patches are coated over their entire surface with a resin-rubber adhesive containing the active ingredient. However, such plasters, which generally have to be applied over a larger area, can occasionally cause mechanical skin irritations after detachment in the case of sensitive patients. Their removal is painful to some extent after prolonged gestation.
  • WO 94/02123 describes an active ingredient patch based on hot-melt adhesive compositions which contains low-melting and / or highly volatile active ingredients in a concentration of 2.5% by weight to 25% by weight.
  • Active substance-containing tapes or wound dressings can only be adequately fixed on joints or thighs due to the mechanical stress. A frequent dressing change is also common to administer suitable active ingredients of the site to be treated at or around the joint.
  • the object of the present invention is therefore also to provide an application improvement for the care of the skin with skin conditions.
  • a skin support according to claim 1.
  • preferred embodiments of the edition are disclosed.
  • the invention also includes their use.
  • the tasks are solved by a care set consisting of a skin support and a wrap.
  • a skin layer comprising a matrix adhering to the human skin, at least one cosmetic active substance, wherein the active substance is contained in the matrix, achieves the stated object.
  • the skin support according to the invention are all cosmetically applicable
  • this is not a medicine-effective active substance but a
  • water-forming polymers polyisobutylenes or cataplasms are preferred.
  • an adhesive based on polyacrylic acid or polyacrylates is preferred.
  • the proportion of water-gelling polymer, e.g. Polyacrylic acid gel in the matrix regulates the adhesion.
  • the matrices disclosed in DE 10260873 and DE 10056010 are herewith part of the present invention.
  • Polyacrylates which are advantageous according to the invention are acrylate-alkyl acrylate copolymers, in particular those selected from the group of the so-called carbomers or carbopols (Carbopol® is a registered trademark of the B.F. Goodrich Company).
  • the acrylate copolymers or copolymers which are advantageous according to the invention are distinguished by the following structure:
  • R ' represents an alkyl radical, in particular a long-chain radical
  • x and y represent numbers which symbolize the respective stoichiometric proportion of the respective comonomers.
  • acrylate copolymers and / or acrylate-alkylacrylate copolymers which are available under the trade names Carbopol® 1382, Carbopol® 981 and Carbopol® 5984 from the BF Goodrich Company, preferably polyacrylates from the group of carbopols of the types 980, 981, 1382, 2984, 5984 and more preferably Carbomer 2001.
  • the water-gel-forming polymer in particular polyacrylic acid and / or copolymers thereof, are preferably used in an amount of 2-55% by weight, more preferably between 5 and 30% by weight.
  • the preparation of the polymer matrices is carried out without using organic solvents, preferably at 40-95 ° C, in commercial mixers / kneaders or continuously in suitable extruders.
  • organic solvents preferably at 40-95 ° C
  • water-gelling polymer u.a. also monkey bread tree flour.
  • water-gelling polymer polyacrylic acid
  • seaweed extract such as alginates and / or agar-agar
  • mono- or polyhydric alcohol mono- or polyhydric alcohol
  • the polymer matrices may be treated with appropriate plasticizers, solubilizers, penetration enhancers, neutralizing agents, e.g. Tromethamol (2-amino-2- (hydroxymethyl) -1, 3-propanediol), triethanolamine (2,2 ', 2 "-Nitrilotriethanol) or NaOH, fillers and / or other known additives are added, but the addition is not mandatory ,
  • Polymer matrix or gel matrix dermatological or cosmetic active ingredients for controlled local or systemic delivery to / in the skin in amounts of up to 35 wt.%, Preferably up to 15 wt.%, In particular up to 2 wt.%.
  • the matrix according to the invention may also be a water-containing application form, an additional cooling effect is achieved per se is already cosmetically pleasant and contributes to well-being. This positive effect can be enhanced by the addition of other nourishing ingredients.
  • glycerol in particular serinol (3-amino-1,2-propanediol) or isoserinol (2-amino-1,3-propanediol) as well as urea and PCA (pyrrolidonecarboxylic acid) can be added as moisturizing substances.
  • serinol 3-amino-1,2-propanediol
  • isoserinol (2-amino-1,3-propanediol) as well as urea
  • PCA pyrrolidonecarboxylic acid
  • Polyisobutylene PIB is also preferably used as the matrix system according to the invention.
  • matrices besides PIB polyisobutylene hydrophobic base polymers such as SIS (styrene / isoprene / styrene) triblock copolymers, SBS (styrene / butadiene / styrene) -
  • Triblock copolymers SBR (copolymers of styrene and butadiene), synthetic and / or natural polyisoprenes, polyamide, polyester, co-polyester, polyurethanes and / or mixtures thereof possible.
  • SBR copolymers of styrene and butadiene
  • synthetic and / or natural polyisoprenes polyamide, polyester, co-polyester, polyurethanes and / or mixtures thereof possible.
  • polyacrylates and polyisobutylenes are particularly preferred.
  • Polyisobutylenes as matrix base meet the requirements of a self-adhesive, skin-friendly and painlessly removable polymer matrix particularly well, so that it is logical to select the polyisobutylenes preferably as the matrix base.
  • SBR is a collective term for copolymers of styrene and butadiene, which contain the two monomers mostly in a weight ratio of about 23.5: 76.5, in exceptional cases also of 40:60 and whose macromolecules predominantly have the structural units I and II:
  • Water-containing matrices according to the invention can be used to moisturize very dry skin areas.
  • the polymer matrix of the invention as a patch, Päd or skin support for the care of the skin and especially for simple cooling purposes extremely well suited and, moreover, self-adhesive equipped, easy to use. It is also advantageous, according to avoid the disadvantages of the prior art, that the polymer matrix is solvent-free.
  • Preferred cosmetic active ingredient is carnitine, 3-hydroxy-4- (trimethylammonium) -butyric acid betaine, of the structure
  • L-form of carnitine is widely distributed in animal tissues and is a characteristic component of the striped musculature v. a in dark meats.
  • L-carnitine is only present in small amounts ( ⁇ 4 mg / 100 g).
  • the total amount of L-carnitine in the human body is about 20-25 g. In heart and skeletal muscle, 98% of the reserves are stored.
  • L-carnitine acts as a carrier molecule in the transport of long-chain fatty acids through the inner mitochondrial membrane into the mitochondrial matrix space, while medium and short-chain fatty acids can pass without esterification with L-camitine.
  • L-carnitine is available in many nutritional supplements. Target groups are (endurance) athletes as well as overweight persons who are offered L-carnitine for performance enhancement or as a slimming product (fat-boomer). The effectiveness is very controversial in both cases. Since L-carnitine deficiency is very rare in healthy people, no benefit is expected from camitine supplementation. Carnitine is not consumed in its biochemical function as a carrier, so that an increase in sales in the field of lipid metabolism does not lead to a greater need for carnitine. Conversely, an additional camitine intake does not result an increase in fatty acid oxidation. An excess of camitin is excreted through the kidney again.
  • L-carnitine can improve cardiac output and overall cardiac resilience by increasing beta-oxidation of fatty acids, increasing ATP levels, reducing blood and tissue fat levels (free fatty acids), and increasing blood flow to the heart increase.
  • L-carnitine is attributed to a certain immune-stimulating function, which is attributed to an increase in the activity of granulocytes, T-lymphocytes and killer cells.
  • a skin dressing according to the invention containing preferably camitin is therefore suitable for the care of skin areas affected by cellulite.
  • a skin pad comprising a combination of an adhesive matrix of polyacrylic acid polymer and the cosmetic active ingredient camitin has been shown to be an advantageous treatment method of the skin affected by striae. It is therefore preferred in accordance with the invention to use the skin layer comprising polyacrylic acid polymers and camitin contained therein for the cosmetic treatment of the skin areas affected by striae.
  • Camitin or its derivatives are used in a proportion of 0.01 to 10 wt.%, Preferably 0.1 to 1 wt.%, In particular 0.5 wt.%, Based on the total mass of the matrix used.
  • Another cosmetic active ingredient in the context of the present invention is preferably caffeine.
  • Caffeine exerts a lipolytic effect on the fatty tissue (increase in free fatty acids). Also known is the diuretic effect of coffee (diuretic).
  • Another preferred active ingredient in the context of the present invention is capsaicin, (E) - ⁇ / - (4-hydroxy-3-methoxybenzyl) -8-methyl-6-nonenamide; FEMA 3404, the structure,
  • Capsaicin as a natural raw material is usually not understood to mean the pure substance, but a mixture of capsaicin-homologous similar physiological action, the so-called capsaicinoids. So describes z. B. the monograph of USP 28 capsaicin with a content of at least 55% capsaicin, the sum of the contents of capsaicin and dihydrocapsaicin with min. 75% and the sum of the contents of all other capsaicinoids, such as. Nordihydrocapsaicin, with at most 15%.
  • capsaicin thus includes all of the following homologs of different composition:
  • the capsaicinoids can be incorporated as a powdery substance mixture as well as in the form of capsaicin-containing extracts of different concentrations.
  • Such extracts are for example, but not limited to, Capsicum oleoresin or as extra ctum Capsici (fluidum) referred to.
  • the capsaicinoids can be used in the form of triturations or pulverizations of the fruit components of the original Scharfpfefferoeuvre, z. B. as so-called chillies powder.
  • nonylic acid vanillylamide also referred to as nonivamide for short.
  • Nonivamid is synthetically produced and accordingly referred to as "synthetic capsaicin.”
  • capsaicinoids cause tingling sensation or heat even in small amounts, for example in the known ABC patches capsaicinoids can be found.
  • capsaicin is understood as meaning all natural and synthetic capsaicinoids in all combinations, such as technical forms of application.
  • the stated proportions of capsaicin relate to the absolute amounts of the particular capsaicinoid / the respective capsaicinoids in the matrix according to the invention and not to the content or the amount of the capsaicin-containing use form of the raw material.
  • these active ingredients are integrated side by side in the self-adhesive matrix and are released from this within the application time to the skin.
  • the ratio of carnitine or its derivatives to capsaicin and / or caffeine is according to the invention preferably in a ratio of 1 to 100 to 1, advantageously 1 to 1. Ie at a preferred fraction of carnitine of 0.5 wt.%, A proportion of 0 , 5% by weight of caffeine has been shown to be extremely effective.
  • the well-known warming effect of capsaicin, in combination with carnitine and its reducing effect of tissue fats results in a reduction of so-called orange peel, cellulite, which is effective even in low concentrations.
  • the inventive composition containing carnitine alone and / or in combination with capsaicin and / or caffeine in the matrix of the skin layer shows a beneficial effect on the skin thus treated, the lymphatic circulation and heat development is stimulated.
  • this synergism is shown positively in a skin layer which is in contact with the skin to be treated for several hours, up to 8 hours.
  • biochinones in particular ubiquinone Q10, creatine, creatinine, carnitine, acetylcamitin, biotin, isoflavone and isoflavonoids, genistein, arctiin, cardiolipin, lipoic acid, anti-freezing proteins, hops and hops malt extracts, and / or the restructuring of the connective tissue promoting substances, isoflavonoids and isoflavonoid-containing plant extracts such as soy and clover extracts that can be very well used in the matrices of the invention.
  • biochinones in particular ubiquinone Q10, creatine, creatinine, carnitine, acetylcamitin, biotin, isoflavone and isoflavonoids, genistein, arctiin, cardiolipin, lipoic acid, anti-freezing proteins, hops and hops malt extracts, and / or the restructuring of the connective tissue promoting substances, isoflavonoids and
  • the matrix is particularly well-suited as active ingredients to support skin functions on dry skin such as vitamin C, biotin, creatine, creatinine, propionic acid, glycerin, green tea extracts, white tea extracts or solutions, eucalyptus oil , Urea and mineral salts such.
  • active ingredients for alleviating or positively influencing irritative skin conditions, be it in sensitive skin in general or in skin irritated by noxious substances (UV light, chemicals), has proven to be advantageous.
  • agents such as sericosides, various extracts of the licorice, licochalcone A, silymarin or silyphos, dexpanthenol, ethanol, inhibitors of prostaglandin metabolism, in particular cyclooxygenase, and leukotriene metabolism, in particular 5-lipoxygenase, but also the 5-lipoxygenase inhibitor Protein, FLAP.
  • modulators of pigmentation also proved to be advantageous.
  • agents that reduce the pigmentation of the skin and thus lead to a cosmetically desired lightening of the skin and / or reduce the occurrence of age spots and / or lighten existing age spots such as tyrosine sulfate, dioic acid (8-hexadecene-1, 16 dicarboxylic acid), lipoic acid and liponamide, various extracts of licorice, kojic acid, hydroquinone, arbutin, fruit acids, especially alpha-hydroxy acids (AHAs), bearberry (Uvae ursi), ursolic acid, ascorbic acid, green tea extracts, aminoguanidine and / or pyridoxamine , Likewise, the matrices of the present invention have been found to provide an excellent basis for enhanced skin faster tanning (Advanced Glycation End Products (AGE), lipofuscins, nucleic acid oligonucleotides, purines and pyrimidines, NO-releasing agents, either with or without influence of UV light.
  • AGE
  • White tea extracts contain a high content of polyphenols, they are among the highly effective antioxidants that make free radicals harmless.
  • the research that deals with these aspects of white tea is still relatively young.
  • White teas are commercially available under the names Yin Zhen (Silver Needle) and Yin Long (Silver Dragon). Preference is therefore given to the use of white tea extract, since in combination with carnitine, the skin nourishing and especially a cellulite-degrading effect could be observed.
  • the matrix as a whole contains, including carnitine, capsaicin and / or caffeine, active ingredients in amounts of up to 35% by weight, preferably up to 15% by weight, very particularly preferably 0.02-2% by weight, based on the total mass of the matrix ,
  • the antioxidants are selected from the group consisting of amino acids, eg glycine, lysine, arginine, cysteine, histidine, tyrosine, tryptophan, and their derivatives (as salt, ester, ether, sugar, nucleotide, nucleoside, Peptide and lipid combination), imidazoles, eg urocaninic acid, and their derivatives, as a salt, ester, ether, sugar, nucleotide, nucleoside, peptide and / or lipid combination, peptides such as D , L-camosine, D-camosine, L-camosine, anserine and their derivatives, eg as a salt, ester, ether, sugar, thiol, nucleotide,
  • ester, ether, sugar, nucleotide, nucleoside, peptide and / or lipid Verbidung, chlorogenic acid and its derivatives as a salt, ester, ether, sugar, thiol , Nucleotide, nucleoside, peptide and / or lipid combination, aurothioglucose, propylthiouracil and other thiols, eg thioredoxin, lipoic acid, glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl , Propyl, amyl, butyl and lauryl, palmitoyl, oleyl, ⁇ -linoleyl, cholesteryl and glyceryl esters, and their salts, dilaurylthiodipropionate, distearylthiodipropionate, thiodipropionic acid and derivatives thereof,
  • (metal) chelators for example apoferritin, desferral, lactoferrin, ⁇ -hydroxyfatty acids, palmitic acid, phytic acid, and their derivatives, as salt, ester, ether, sugar, thiol, nucleotide, nucleoside, Peptide and / or lipid association, ⁇ -hydroxy acids, eg citric acid, lactic acid, malic acid, humic acid, bile acid, bile extracts, bilirubin, Biliverdin, melanin, EDTA, EGTA and their derivatives, unsaturated fatty acids and their derivatives, eg ⁇ -linolenic acid, linoleic acid, oleic acid, folic acid and its derivatives, furfurylidenesorbitol and its derivatives, ubiquinone, ubiquinol, plastoquinone and their derivatives, as salt, ester -, ether, sugar, thiol, nucle
  • Zinc and its derivatives for example ZnO, ZnSO 4 , selenium and its derivatives, for example selenium methionine, ebselen, stilbenes and their derivatives, for example stilbene oxide, trans-stilbene oxide, and the derivatives suitable according to the invention, as the salt, ester, ether, sugar -, thiol, nucleotide, nucleoside, peptide and / or lipid Verbidung, these agents mentioned.
  • the matrix will contain the antioxidant (s) in amounts of 0-35% by weight, preferably 0-15% by weight, most preferably 0.02-2%.
  • active ingredients furthermore, for example, essential oils can be used.
  • Essential oils are understood to be plant-derived concentrates, which are used as natural raw materials mainly in the perfume and food industry and consist more or less of volatile compounds. As examples of these compounds may be mentioned 1,8-cineole, limonene, menthol, borneol and camphor. Often the term essential oils is used for the volatile ingredients still contained in the plants. In the true sense, however, essential oils are mixtures of volatile components which are produced by steam distillation from vegetable raw materials.
  • Essential oils consist exclusively of volatile components whose boiling points are generally between 150 and 300 ° C. They contain mostly
  • Hydrocarbons or monofunctional compounds such as aldehydes, alcohols, Esters, ethers and ketones.
  • Parent compounds are mono- and sesquiterpenes, phenylpropane derivatives and longer-chain aliphatic compounds.
  • Some essential oils are dominated by an ingredient, for example eugenol in clove oil, with more than 85%, while other essential oils are complex mixtures of the individual components.
  • the organoleptic properties are not influenced by the main components, but by side or trace components, such as Example of the 1,3,5-undecatrienes and pyrazines in galbanum oil.
  • the number of identified components is in the hundreds. Very many ingredients are chiral, very often one enantiomer predominates or is exclusively present, such as (-) - menthol in peppermint oil or (-) - linalyl acetate in lavender oil.
  • Oleum Eucalypti Oleum Menthae piperitae, Oleum camphoratum, Oleum Rosmarini, Oleum Thymi, Oleum pinis sibricum, and Oleum Pini silverstris, as well as the terpenes 1,8-cineol and levomethanol, may be mentioned as preferred essential oils.
  • Peppermint oils are essential oils obtained by steam distillation from leaves and inflorescences of various peppermint varieties, occasionally also from Mentha arvensis.
  • Citrus oils are essential oils derived from the peel of citrus fruits (bergamot, grapefruit, lime, mandarin, orange, lemon), often called citrus oils.
  • Citrus oils consist to a large extent of monoterpene hydrocarbons, mainly limonene (exception: bergamot oil, which contains only about 40%).
  • menthol can be used to surface anesthetize skin irritation caused by mild burns.
  • the products produced in this way create a pleasant feeling of coldness and can be used to cool skin irritations, eg mild sunburn and razor bumps, which do not require any specialist treatment.
  • Menthol has three asymmetric carbon atoms and therefore exists in four diastereomeric pairs of enantiomers (see the formula pictures, the other four enantiomers are the corresponding mirror images).
  • neoisomenthol The diastereomers which can be separated by distillation are referred to as neoisomenthol, isomenthol, neomenthol [(+) - form: constituent of Japanese peppermint oil] and menthol.
  • the most important isomer is (-) - menthol (levomenthol), shiny, strongly peppermint-smelling prisms.
  • camphor may be added for the treatment of skin irritation / mild pain, neuralgia and inflammation of the matrix.
  • Camphor is 2-bomanone, 1, 7,7-trimethylbicyclo [2.2.1] heptan-2-one, see figure below. (+) - camphor
  • hyperemic active substances such as synthetic active substances such as nicotinic acid derivatives, preferably benzyl nicotinate or propyl nicotinate, may also be mentioned, or antiphlogistics and / or analgesics.
  • flavone and its derivatives are advantageous additives in the sense of the present invention, characterized by the following basic structure (substitution positions indicated):
  • flavones usually occur in glycosidated form.
  • the flavonoids are preferably selected from the group of substances of the generic structural formula
  • Z 1 to Z 7 are independently selected from the group consisting of H, OH, alkoxy and hydroxyalkoxy, where the alkoxy or hydroxyalkoxy groups can be branched and unbranched and can have 1 to 18 C atoms, and wherein GIy is selected is selected from the group of mono- and oligoglycoside radicals.
  • the flavonoids can also be chosen advantageously from the group of substances of the generic structural formula
  • Z 1 to Z 6 are independently selected from the group consisting of H, OH, alkoxy and hydroxyalkoxy, where the alkoxy or hydroxyalkoxy groups can be branched and unbranched and can have 1 to 18 C atoms, and wherein GIy is selected from the group of mono- and oligoglycoside radicals.
  • such structures can be selected from the group of substances of the generic structural formula
  • Glyi, Gly 2 and Gly 3 independently represent monoglycoside radicals or.
  • GIy 2 or GIy 3 can also represent individually or jointly saturations by hydrogen atoms.
  • Glyi, Gly 2 and Gly 3 are preferably selected independently of one another from the group of the hexosyl radicals, in particular the rhamnosyl radicals and glucosyl radicals.
  • hexosyl radicals for example allosyl, altrosyl, galactosyl, gulosyl, idosyl, mannosyl and talosyl, may also be advantageous to use. It may also be advantageous according to the invention to use pentosyl radicals.
  • Z 1 to Z 5 are independently selected from the group H, OH, methoxy, ethoxy and 2-hydroxyethoxy, and the flavone glycosides have the structure
  • Glyi, Gly 2 and Gly 3 independently represent monoglycoside or oligoglycoside residues.
  • GIy 2 or GIy 3 can also individually or together represent hydrogen atom saturation.
  • Glyi, Gly 2 and Gly 3 are preferably selected independently of one another from the group of the hexosyl radicals, in particular the rhamnosyl radicals and glucosyl radicals.
  • hexosyl radicals for example allosyl, altrosyl, galactosyl, gulosyl, idosyl, mannosyl and talosyl, may also be advantageous to use. It may also be advantageous according to the invention to use pentosyl radicals.
  • flavone glycoside (s) from the group ⁇ -glucosylrutin, ⁇ -glucosylmyricetin, ⁇ -glucosylisoquercitrin, ⁇ -glucosylisoquercetin and ⁇ -glucosylquercitrin.
  • Particularly preferred according to the invention is ⁇ -glucosylrutin.
  • Naringin (aurantiin, naringenin-7-rhamnoglucoside), hesperidin (3 ', 5,7-trihydroxy-4'-methoxyflavanone-7-rutinoside, hesperidoside, hesperetin-7-O-rutinoside) are also advantageous according to the invention.
  • Rutin (3,3 ', 4', 5,7-pentahydroxyfly of 3-rutinoside, quercetin-3-rutinoside, sophorin, birutane, rutabion, taurutin, phytomelin, melin), troxerutin (3,5-dihydroxy-3 ⁇ 4 ⁇ 7-tris (2-hydroxyethoxy) -flavone-3- (6-O- (6-deoxy- ⁇ -L-mannopyranosyl) - ⁇ -D-glucopyranoside)), monoxerutin (3,3 ', 4 ', 5-tetrahydroxy-7- (2-hydroxyethoxy) flavone-3- (6-O- (6- deoxy-.alpha.-L-mannopyranosyl) .beta.-D-glucopyranoside), dihydrorobinetine (3,3 ', 4', 5 ', 7-pentafluorooxyflavanone), taxifolin (3,3', 4 '
  • the skin layer according to the invention preferably comprises carnitine as the active ingredient and polyacrylic acid as the basis of the adhesive matrix has, on the one hand, good adherence to the skin, which must be maintained over the entire period of the intended active ingredient dosage, and, on the other hand, residue-free and painless removability.
  • a skin support according to the invention in which a combination of preferred polyacrylate adhesive (sodium polyacrylate / polyacrylic acid sol. 20%), carnitine is selected as the cosmetic active ingredient and the following constituents of the support:
  • the material of the patch As a significant influence on the pressure is the material of the patch and its nature to look at. For example, if it is a relatively flexible, elastic material, then the material can dodge the pressure generated when applied to the skin. Pressure on the skin is not achieved. However, if the paving material is rigid and inflexible, it is detrimental to a long wearing time and the comfort of the patient. Other influencing factors on the pressure exertion, which indirectly also have something to do with the paving material properties, are
  • these influencing variables are selected by the preferred ones
  • compositions of the adhesive matrix, the carrier material and the cosmetic active ingredients optimally coordinated.
  • adhesion time-value (adhesion time-value) of greater than 5 s.
  • the adhesion time-value becomes after one
  • Standard measurement methodology is determined, as outlined below.
  • Figure 1 shows a sloping plane with a slope of 30 ° on which a test skin with the adhesive side (3) is placed up.
  • the upper and lower part is covered by a cardboard (2), so that a distance of 5 cm is maintained.
  • the steel ball (1) is placed at the top of the inclined plane.
  • steel balls (diameter 19.0 mm, mass 28.2 g) are first cleaned in toluene and then in anhydrous acetone of fat residues and other impurities.
  • the evaporation time of the solvent to use the steel balls must be at least 2 minutes and may not exceed 10 minutes.
  • the self-adhesive skin layer to be tested is placed with the support side downwards in the middle on an inclined plane (30 °), so that the support ends overlap the markings attached to the side of the inclined plane. Then by means of a Sheet of paper (standard copy paper or equivalent quality) the top of the inclined plane, starting from the top edge, covered over a length of 10 cm, that paper possibly folded over the edge and secured to a steel pin against slipping. Below the covered part of the inclined plane follows the test section of the skin support with the exposed adhesive layer. Length of the respective measuring section is 5 cm. Subsequently, the lower part of the plane, starting from the lower end of the respective measuring section, also covered with paper.
  • a Sheet of paper standard copy paper or equivalent quality
  • the steel ball must be held within the exposed area of the skin pad for at least 5 seconds from the adhesive layer of the supports to meet the adhesive requirement, i.e. achieve an adhesion time-value greater than 5.
  • the skin pads of the present invention comprising the following ingredients exhibit a corresponding adhesion time-value.
  • the invention adhering to the human skin matrix containing camitine as a cosmetic active ingredient has an adhesion time-value of greater than 5 and thus has the necessary characteristics to the requirements of the bond strength over the period of application (up to 8 h), a pain - And residue-free removability and a skin-friendly bond to meet.
  • patch or cosmetic matrix / cosmetic pedicle matrices are pressed as a layer on a release medium of paper, foil o. ⁇ ., Rolled o. ⁇ . And on the back with any support material such. a polymer film, textiles o.a. concealed.
  • the matrices are preferably applied to a carrier material in the warm state by means of a dosing pump and most preferably by a corresponding cavity in the press or rolling mills in a three-dimensional form.
  • the shape of the generated patch or cosmetic matrix is determined by the shape of the cavities and is not subject to any restriction; be ellipsoidal running with flat edges or, for example, angular.
  • the matrix according to the invention is particularly advantageously applied to a flexible covering layer, in particular when used as a skin layer, plaster or cosmetic matrix.
  • An appropriate plaster or a corresponding cosmetic matrix of a carrier such as films, nonwovens, woven fabrics, foams, etc., of the adhesive matrix and covering film, covering paper or release paper for protecting the adhesive matrix prior to the use of the plaster, is built up.
  • carrier polymer films are used as the carrier polymer films, nonwovens, fabrics and combinations thereof.
  • support materials u.a. Polymers such as polyethylene, polypropylene, polyesters, polyethers, polyether-ester copolymers and polyurethane or natural fibers to choose from.
  • carrier materials that can be used so that they meet the characteristics of a functional skin layer.
  • textiles such as woven fabrics, knitted fabrics, scrims, nonwovens, laminates, nets, films, foams and papers are listed, which have a pleasant feel for the user.
  • these materials can be pre- or post-treated.
  • common Pretreatments are corona and hydrophobing;
  • Common aftertreatments include calendering, tempering, laminating, stamping and covering.
  • the carrier material can be sterilized, preferably ⁇ - (gamma) sterilizable.
  • Very particularly preferred according to the invention are support materials having a good oxygen, air and water vapor permeability.
  • these support materials can be provided by screen printing or analogous processes selectively with strongly adhesive polymers such as polyisobutylene, SEBS block polymers, natural and / or synthetic rubbers, polyurethane o. ⁇ . Which overlap at the side edges of the applied hydrogel matrix to the outside.
  • strongly adhesive polymers such as polyisobutylene, SEBS block polymers, natural and / or synthetic rubbers, polyurethane o. ⁇ . Which overlap at the side edges of the applied hydrogel matrix to the outside.
  • the matrices of the invention prepared in this way can be adhesively fixed to parts of the body which are subject to high mechanical stress, such as elbows or knee joints, where the own adhesion of the hydrogels / cataplasms is no longer sufficient for permanent application.
  • the matrix can be covered or provided with an adhesive-repellent carrier material, such as siliconized paper.
  • an adhesive-repellent carrier material such as siliconized paper.
  • the cosmetic matrix according to the invention is usually covered over its entire width until use with an adhesive-repellent carrier material. This protects the self-adhesive layer from the well skin-compatible adhesive of the gel matrix, which has preferably been applied by the transfer process, and additionally stabilizes the entire product.
  • the cover may be formed in one piece or preferably in two parts in a known manner.
  • inventions may be such that there is a second matrix of higher drug solubility as a reservoir between the back of the matrix and the cap support.
  • This could be a deep-drawn film with a pure active substance instead of a second matrix and carrier.
  • On the adhesive side of the matrix is partially, for example, at the edge, a second matrix with high bond strength for additional fixation, but insufficient drug solubility.
  • the drug-free matrix is located between two non-anchoring films and is used for fixation.
  • the present invention furthermore relates to the use of the skin care composition for the care of the skin, in particular those parts of the skin which are affected by cellulite or stria.
  • the use of the drug-doped gel matrices for use as PADs for the cosmetic and beneficial treatment of undesired skin manifestations, such as cellulite or stria is to be emphasized.
  • the use of the polymer matrix as cosmetic or dermatological pads or patches is particularly suitable in a planar embodiment with a total area of 0.2 to 1000 cm 2 . Preferably in an area of 8 to 15 cm to 10 to 20 cm. Thus, for example, large areas (up to 1000 cm 2 ) are covered to treat the orange peel on the thighs.
  • the shape can be designed round, oval, angular or adapted to the skin.
  • the invention further includes combining the skin patch with a wrap compressing the skin to a certain pressure.
  • Pressure values of the applied on the human skin pads or sets have been determined.
  • the measurement was carried out in a uniaxial tensile test according to DIN 53835 - tensile stress with repeated stress between constant strain limits and immediate reversal at the reversal points.
  • the upper yield strength was set at 30%. It was determined the strain-related tensile force of the support under load in the 5th cycle for the elongation, the stretching of the support after application to the leg enclass.
  • the Laplace equation was used to calculate the pressure of the traction, leg circumference, and circumference or circumference.
  • the inventively determined pressures were between about 4 - 7 mmHg. Pads according to the invention comprising such pressure values are therefore preferred.
  • the Sez is designed as described above, so that a maximum pressure of 10 mm Hg is generated on the skin.
  • a wrapping is known from the prior art, which is called "wrapping", whereby a kind of cellophane wrap is pulled over the cellulite-affected areas of the skin.
  • wrapping whereby a kind of cellophane wrap is pulled over the cellulite-affected areas of the skin.
  • a disadvantage is the fully occlusive skin covering, which can lead to skin macerations, itching and other unpleasant skin symptoms.
  • wrapping bandages tape, stockings, pants and / or cuffs can be considered as well as combinations thereof.
  • a sleeve is preferably used as a wrapping, which is to some extent elastic and permeable to air and water vapor.
  • the cuff preferably has a conical section. As a result, an adverse higher compression at the upper thigh portion located to the hip is avoided when putting on the thigh.
  • the cuff is equipped with one end adhering to itself, so that it can be attached to itself.
  • the cuff thus includes all common sizes due to the elasticity and the self-closing properties and it is advantageously created for the manufacturer "one size fits it all" situation.
  • markings are provided on the cuff, which allow the user to easily create depending on the thigh circumference sufficient compression with the cuff.
  • a carrier material for the cuff numerous materials on film, fabric, knitted fabric, nonwoven, gel or foam base are already known and are also used in practice. The materials must be tolerated by the skin, permeable to air and water vapor, as well as easy to model and cuddly. Because of these requirements, a carrier which is as thin or as soft as possible is often preferred. For handling and use of the support materials but also a sufficient strength and possibly limited elasticity are required. Furthermore, the support material should have sufficient strength and low ductility even after wetting.
  • Thin carriers in particular those made of nonwovens, are well permeable to air and water vapor.
  • Suitable support materials are stretchable fabrics of synthetic and natural raw materials.
  • carrier materials that can be used that they meet the properties of a functional association.
  • textiles such as wovens, knits, fabrics, nonwovens, laminates, nets, films, foams and papers are listed which have a ductility of at least 10% under a load of 10 N / cm.
  • the combinations of the materials mentioned are also suitable.
  • Common pretreatments are corona and hydrophobing;
  • Common aftertreatments are calendering, tempering, laminating, stamping and covering, UV / IR irradiation or electron irradiation.
  • the invention thus advantageously comprises a combination of self-adhesive skin layer and cuff according to the invention.
  • This combination is predestined as a set for skin care and especially for cellulite treatment.
  • the kit according to the invention may comprise in use a cuff and 4 to 10 skin pads, so that a long-term and therefore effective treatment is ensured.
  • the skin layer according to the invention containing advantageously carnitine or carnitine and capsaicin, is applied to the lateral thigh area, for example. Due to the self-adhesive property of the skin layer with an adhesion time-value> 5, this is immediately fixed and does not slip. Subsequently, the user can possibly fold over the cuff and, due to the self-closing end, simply close it depending on the desired degree of compression and thigh size.
  • a preferred application time is up to 8 hours, so that according to the invention the skin layer can preferably be worn overnight.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une compresse pour la peau, pourvue d'une matrice adhérant à la peau et contenant au moins un principe actif cosmétique, ainsi qu'une combinaison avec un enveloppement pour la peau destiné à produire une compression efficace pour traiter la cellulite et/ou les vergetures.
EP06725393A 2005-05-13 2006-03-29 Compresse autocollante pour la peau et ensemble combine pour le soin cosmetique de la peau Withdrawn EP1885459A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102005023149 2005-05-13
DE102005053909A DE102005053909A1 (de) 2005-05-13 2005-11-11 Selbstklebende Hautauflage und Kombinationsset zur kosmetischen Hautpflege
PCT/EP2006/061137 WO2006120066A1 (fr) 2005-05-13 2006-03-29 Compresse autocollante pour la peau et ensemble combine pour le soin cosmetique de la peau

Publications (1)

Publication Number Publication Date
EP1885459A1 true EP1885459A1 (fr) 2008-02-13

Family

ID=36636337

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06725393A Withdrawn EP1885459A1 (fr) 2005-05-13 2006-03-29 Compresse autocollante pour la peau et ensemble combine pour le soin cosmetique de la peau

Country Status (4)

Country Link
US (2) US8101216B2 (fr)
EP (1) EP1885459A1 (fr)
DE (1) DE102005053909A1 (fr)
WO (1) WO2006120066A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006060439A1 (de) 2006-12-19 2008-06-26 Henkel Kgaa Verbesserung der Hautverträglichkeit von hyperämisierenden Wirkstoffen
DE102007009650A1 (de) 2007-02-26 2008-08-28 Beiersdorf Ag Kosmetisches Kombinationsprodukt zur Verbesserung des äußeren Erscheinungsbildes
DE102007046541A1 (de) 2007-09-27 2009-04-02 Beiersdorf Ag Anti Cellulite Massage Pad
US8053004B2 (en) * 2007-10-08 2011-11-08 Starmaker Products, Llc Ointment for topical treatment of hot flashes and method of use
US8303982B2 (en) * 2009-03-20 2012-11-06 Ethicon, Inc Self-locating, multiple application, and multiple location medical patch systems and methods therefor
US9999702B2 (en) * 2010-04-09 2018-06-19 Kci Licensing Inc. Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds
GB201110777D0 (en) 2011-06-24 2011-08-10 Aqua Bio Technology Asa Methods and uses
GB201110783D0 (en) 2011-06-24 2011-08-10 Aqua Bio Technology Asa Methods and uses
DE102011081818A1 (de) * 2011-08-30 2013-02-28 Beiersdorf Ag Wirkstoffhaltige Hautauflagen
DE102012212928A1 (de) * 2012-07-24 2014-01-30 Beiersdorf Ag Verwendung von alpha-Glucosylrutin zur verbesserten Hautkonturierung bzw. gegen Cellulite
EP2698136A1 (fr) 2012-08-17 2014-02-19 Gordon Teigelkämper Pansement cosmétique
ES2482441B1 (es) * 2012-11-20 2015-03-31 Universidad De Sevilla Uso de la L-carnitina en productos cosméticos dermatológicos para el tratamiento de estrías y cicatrices
CN105025906B (zh) 2012-12-21 2020-08-25 阿克生物科技公司 来自鱼孵化液的化妆品组合物
GB201223330D0 (en) 2012-12-21 2013-02-06 Aqua Bio Technology Asa Products, methods and uses
WO2015089310A1 (fr) * 2013-12-11 2015-06-18 Atkinson Oscar Revêtement cutané occlusif
WO2015120202A1 (fr) * 2014-02-05 2015-08-13 Skara, Llc Appareil et procédés pour le traitement et la prévention des vergetures et des cicatrices
EP2939650A1 (fr) * 2014-04-29 2015-11-04 LTS LOHMANN Therapie-Systeme AG Pansement pour le traitement de dermatite
RU2629392C1 (ru) * 2016-04-03 2017-08-29 Открытое акционерное общество "Новосибхимфарм" Антицеллюлитный пластырь с экстрактом перца
RU2627586C1 (ru) * 2016-04-03 2017-08-09 Открытое акционерное общество "Новосибхимфарм" Антицеллюлитный пластырь
GB201621818D0 (en) 2016-12-21 2017-02-01 Aqua Bio Tech Asa Cosmetic composition and use thereof
CN110621192B (zh) * 2017-06-29 2022-08-12 松下知识产权经营株式会社 片材、图像处理装置以及图像处理方法
KR101983566B1 (ko) * 2018-03-09 2019-05-29 닥터 레이몬드 래보라토리 피부 외용제 조성물
DE102018211412A1 (de) * 2018-07-10 2020-01-16 Beiersdorf Ag Selbstklebende flächige Produkte enthaltend ein oder mehrere Alkylamidothiazole
BE1026340B1 (nl) * 2018-10-22 2020-01-07 Sylphar Nv Samenstelling voor lokale cutane toediening en gebruik daarvan
KR102076551B1 (ko) * 2018-11-16 2020-02-13 라스텔라 주식회사 사방 결정구조의 피부 외용제 조성물

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759901A (fr) * 1969-12-04 1971-06-04 Ortho Pharma Corp O-(nitroaryl) oximes de 3-cetosteroides
US3790533A (en) * 1972-01-26 1974-02-05 C Samour Pressure sensitive adhesive copolymers and tapes therefrom
US3900610A (en) * 1973-04-09 1975-08-19 Monsanto Co Process of making a pressure sensitive adhesive article
LU85643A1 (fr) * 1984-11-16 1986-06-04 Oreal Composition cosmetique thermo-amincissante a base d'extraits vegetaux oleosolubles
EP0303445A1 (fr) 1987-08-13 1989-02-15 Walton S.A. Pansement pour l'administration transdermique de clébopride
DE3743947A1 (de) * 1987-09-01 1989-03-09 Lohmann Gmbh & Co Kg Vorrichtung zur gesteuerten abgabe von nicotin, verfahren zu ihrer herstellung sowie ihre verwendung
DE3743946A1 (de) * 1987-09-01 1989-03-09 Lohmann Gmbh & Co Kg Vorrichtung zur abgabe von nitroglycerin an die haut, verfahren zu ihrer herstellung sowie ihre verwendung
US5306502A (en) * 1987-09-01 1994-04-26 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Apparatus for delivering nitroglycerin to the skin, processes for the production thereof and the use thereof
US5273757A (en) * 1987-09-01 1993-12-28 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Apparatus for the delivery of substances, processes for the production thereof and use thereof
CA2038902A1 (fr) 1990-04-13 1991-10-14 Randall Paul Sweet Adhesifs autocollants a base de silicone fusible a chaud, avec additif fluide a base de siloxane phenyle; methodes et produits connexes
US5162410A (en) * 1990-04-13 1992-11-10 Dow Corning Corporation Hot-melt silicon pressure sensitive adhesives with phenyl-containing siloxane fluid additive and related methods and articles
JP3146002B2 (ja) 1990-11-09 2001-03-12 帝國製薬株式会社 経皮投与製剤
FR2669537B1 (fr) 1990-11-28 1993-02-19 Oreal Composition amincissante a base d'alpha-2-bloqueurs.
US5196259A (en) * 1990-12-07 1993-03-23 The Dow Chemical Company Matrix composites in which the matrix contains polybenzoxazole or polybenzothiazole
JP3115625B2 (ja) 1991-03-30 2000-12-11 帝國製薬株式会社 リドカイン含有外用貼付剤
US5215759A (en) * 1991-10-01 1993-06-01 Chanel, Inc. Cosmetic composition
DE4222334A1 (de) 1992-07-08 1994-01-13 Beiersdorf Ag Schmelzhaftkleber für Medical-Produkte
DE4224325C1 (de) * 1992-07-23 1994-02-10 Sanol Arznei Schwarz Gmbh Wirkstoffpflaster für niedrigschmelzende und/oder flüchtige Wirkstoffe und Verfahren zu seiner Herstellung
DE4310012A1 (de) 1993-03-27 1994-09-29 Roehm Gmbh Dermales therapeutisches System aus einer schmelzfähigen Poly(meth)acrylat-Mischung
US5482988A (en) 1994-01-14 1996-01-09 Dow Corning Corporation Hot-melt silicone pressure sensitive adhesive with siloxylated polyether waxes as additives
US5572536A (en) * 1994-05-26 1996-11-05 Texas Instruments Incorporated Digital circuitry with improved parallel signature analysis capability
US5523090A (en) 1995-02-24 1996-06-04 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Skin treatment composition
FR2756754B1 (fr) 1996-12-09 1999-02-19 Novacarb Composition de traitement de fumees et utilisations
WO1999036032A1 (fr) * 1998-01-15 1999-07-22 Lavipharm Laboratories, Inc. Activateur de penetration renfermant un lipide polaire vegetal dans un timbre cosmetique et servant a ameliorer l'apparence de la peau
JPH11228340A (ja) 1998-02-12 1999-08-24 Nitto Denko Corp 化粧用ゲルシート
DE19825693C2 (de) * 1998-06-09 2001-09-27 Rudolf Weyergans Verfahren und Mittel zur Verbesserung der körperlichen Erscheinung
US6335088B1 (en) 1998-07-06 2002-01-01 Daiya Pharmaceutical Co., Ltd. Moisture-retentive cooling gel, moisture-retentive cooling gel laminate, and moisture-retentive cooling plaster
FR2781667B1 (fr) 1998-07-30 2001-06-01 Oreal Patch cosmetique, pharmaceutique, ou dermatologique
US6623751B2 (en) * 1998-07-30 2003-09-23 L'oreal S.A. Cosmetic, pharmaceutical, or dermatological patch
TW575430B (en) 1998-12-03 2004-02-11 Kao Corp Sheet cosmetics
DE19911262C2 (de) 1999-03-13 2003-04-10 Scs Skin Care Systems Gmbh Vorrichtung zur Abgabe kosmetischer Wirkstoffe
US6698162B2 (en) * 2000-03-23 2004-03-02 Teikoku Pharma Usa, Inc. Methods of producing a terminally sterilized topical patch preparation
DE10028718A1 (de) * 2000-06-09 2001-12-13 Henkel Kgaa Kosmetische Stifte
US6589194B1 (en) * 2000-06-23 2003-07-08 C-Boot Ltd Self-powered compression devices and methods for promoting circulation and therapeutic compression
FR2813187B1 (fr) 2000-08-22 2003-01-17 Oreal Composition, notamment cosmetique, comprenant une sapogenine et une base xanthique
DE10056010A1 (de) * 2000-11-11 2002-05-16 Beiersdorf Ag Pflaster mit hautpflegenden Substanzen
EP1234572B1 (fr) * 2001-02-26 2013-10-30 Mibelle AG Cosmetics Produits de soin pour la peau contenant de l'isoflavone aglycone
US20020192273A1 (en) * 2001-06-15 2002-12-19 Teri Buseman Therapeutic patch useful for the treatment of hemorrhoids
ITRM20010364A1 (it) * 2001-06-25 2002-12-27 Biosalts Srl Ascorbil derivati di carnitine e composizioni cosmetiche contenenti tali derivati.
US20030082217A1 (en) * 2001-10-25 2003-05-01 Isabelle Afriat Use of heat-stabilizing microcapsules to improve the activity or penetration of cosmetic or pharmaceutical active principles
US20030152612A1 (en) * 2002-01-03 2003-08-14 Pugliese Peter T. Method and article to control cellulite
US20040228884A1 (en) * 2003-05-15 2004-11-18 Gupta Shyam K. Ion-pair delivery system for cosmetic and pharmaceutical compositions
US7098189B2 (en) * 2002-12-16 2006-08-29 Kimberly-Clark Worldwide, Inc. Wound and skin care compositions
DE10260872B4 (de) * 2002-12-23 2013-09-26 Beiersdorf Ag Verwendung von gelbildendem Polymer, Wasser, Alkohol und Meeresalgenextrakt zur Einstellung von Elastizität und Haftvermögen selbstklebender kosmetischer Polymermatrices
DE10260873A1 (de) * 2002-12-23 2004-07-15 Beiersdorf Ag Selbstklebende Polymermatrix mit einem Gehalt an Meeresalgenextrakt und Glycerin
US20040143026A1 (en) * 2002-12-31 2004-07-22 Shah Kishore R. Bioadhesive hydrophilic composition for treatment of mammalian skin
US20040161435A1 (en) * 2003-02-14 2004-08-19 Gupta Shyam K. Skin Firming Anti-Aging Cosmetic Mask Compositions
ITMI20030315A1 (it) 2003-02-21 2004-08-22 Vama Farmacosmetica S R L Sale di carnitina, preliposoma che lo contiene e formulato dermocosmetico per uso topico a base del detto sale di carnitina.
US20040175351A1 (en) * 2003-03-03 2004-09-09 Kay Liu Compositions and methods for reducing or controlling oxidants and aging
JP2006524236A (ja) 2003-04-24 2006-10-26 アモレパシフィック コーポレーション スリミング用組成物
DE10330971B4 (de) * 2003-07-08 2007-03-29 Beiersdorf Ag Verfahren zur Herstellung von Haut- oder Wundauflagen mit verkapselten, wundheilungsfördernden und/oder hautpflegenden Substanzen
CH693819A5 (it) 2003-07-21 2004-02-27 Gecomwert Anstalt Preparato contro gli inestetismi cutanei della cellulite.
US20060134147A1 (en) * 2004-12-21 2006-06-22 Avon Products, Inc. Cosmetic compositions having carnitine creatinate and methods for using

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006120066A1 *

Also Published As

Publication number Publication date
US8101216B2 (en) 2012-01-24
WO2006120066A1 (fr) 2006-11-16
US20120089105A1 (en) 2012-04-12
US20080038300A1 (en) 2008-02-14
DE102005053909A1 (de) 2006-11-16

Similar Documents

Publication Publication Date Title
EP1885459A1 (fr) Compresse autocollante pour la peau et ensemble combine pour le soin cosmetique de la peau
EP2750644B1 (fr) Pansement contenant des principes actifs
DE3779999T2 (de) Erhoehung des penetrationsvermoegens mittels eines aus die zellhuelle veraendernden substanzen und kurzkettigen alkoholen bestehenden binaeren systems.
JP2009519940A (ja) 皮膚科学的状態を処置するための組成物および方法
WO2004058211A1 (fr) Matrice polymere autocollante contenant un extrait de sel marin
DE4241874A1 (de) Medizinisches Pflaster für die perkutane Verabreichung
EP2460531B1 (fr) Collagène pour l'utilisation dans le traitement de maladies de la peau
EP2744474A1 (fr) Composition médicale de protection de la peau comprenant une combinaison de principes actifs améliorant la barrière cutanée
WO2018224099A1 (fr) Coussinet en silicone comprenant des principes actifs pour les soins de la peau et contre le vieillissement de la peau
JP4677063B2 (ja) オランダカラシエキス配合外用製剤
EP3283055A1 (fr) Combinaison de substances naturelles contenant au moins un acide glycyrrhétinique et au moins un guggulstérone, et utilisation de cette dernière pour des applications cosmétiques
DE202006019183U1 (de) Sanddorn-Hautpflegeöl
EP1317257B1 (fr) Emplatre
CN112057386A (zh) 一种清爽保湿美白修复的防晒乳及其制备方法
CN101175537A (zh) 自粘性的皮肤贴片和用于美容皮肤护理的组合套件
US10786441B2 (en) Skin barrier repair and maintenance composition
DE102014113770A1 (de) Pflaster mit öligen Pflanzenextrakten
DE202006019184U1 (de) Feuchtigkeitsspendendes Sanddorn-Hautpflegegel
DE10049225A1 (de) Dermales System, enthaltend Diclofenac
KR20110101097A (ko) 비타민 경피흡수제제
RU2681851C1 (ru) Противоожоговое средство
DE102006001162A1 (de) Pflasterabdeckung bei atopischer Dermatitis
DE202022106557U1 (de) Netz-Gesichtsmaske
DE20221248U1 (de) Kosmetisches Pad mit einer selbstklebenden Polymermatrix auf Polyacrylsäurebasis mit einem Gehalt an Meeresalgenextrakt und Glycerin
DE202006019185U1 (de) Feuchtigkeitsspendendes, wasserhaltiges Sanddorn-Hautpflegepräparat

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071213

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

RIN1 Information on inventor provided before grant (corrected)

Inventor name: WOELLER, KARL-HEINZ

Inventor name: SCHULZ, JENS

Inventor name: POST, KATHARINA

Inventor name: BODENSCHATZ, STEFAN

Inventor name: GAEDE, CHRISTIAN

Inventor name: HARTKOPF, CARSTEN

Inventor name: JASPERS, SOEREN

17Q First examination report despatched

Effective date: 20081106

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090519